Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Liposarcoma × pemigatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Cholangiocarcinoma 10 Acrocephalosyndactylia 6 Carcinoma, Transitional Cell 5 Neoplasm Metastasis 4 Breast Neoplasms 4 Gastrointestinal Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Stomach Neoplasms 2 Solid Tumor 2 Recurrence 2 Pancreatic Neoplasms 2 Neoplasms 2 Myeloproliferative Disorders 2 Lung Neoplasms 2 Endometrial Neoplasms 2 Colorectal Neoplasms 2 Carcinoma 2 Urinary Bladder Neoplasms 1 Solid Tumor, Miscellaneous 1 Sarcoma 1 Oligodendroglioma 1 Non-Muscle Invasive Bladder Neoplasms 1 Neoplasms, Unknown Primary 1 Multiple Myeloma 1 Lymphoma, Mantle-Cell 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma, B-Cell 1 Locally Advanced Unresectable Gastric Cancer 1 Liposarcoma 1 Leukemia, Myeloid, Acute 1

Interventions

Doxorubicin 25 Radiotherapy 15 Ifosfamide 14 Trabectedin 10 pazopanib 6 ribociclib 5 pembrolizumab 5 Specimen Handling 5 Gemcitabine 5 Biopsy 5 palbociclib 4 Magnetic Resonance Spectroscopy 4 Docetaxel 4 Cyclophosphamide 4 Chemotherapy, Adjuvant 4 selinexor 3 liposomal doxorubicin 3 eribulin 3 X-Rays 3 Vincristine 3 Radiation 3 Neoadjuvant Therapy 3 Imatinib Mesylate 3 Filgrastim 3 Etoposide 3 toripalimab 2 temsirolimus 2 romidepsin 2 pegfilgrastim 2 cixutumumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06389799 2025-08-28

PERELI

Lund University Hospital

Phase 2 Recruiting

Liposarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡